E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Cerebral edema following Large Hemispheric Infarction |
edema cerebrale a seguito di infarto emisferico massivo |
|
E.1.1.1 | Medical condition in easily understood language |
Brain swelling after stroke |
Gonfiore del cervello a seguito di stroke |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008107 |
E.1.2 | Term | Cerebral edema |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). |
L’obiettivo primario è determinare se BIIB093 migliora l’esito funzionale al Giorno 90, misurato mediante la scala di Rankin modificata (mRS), rispetto al placebo nei soggetti con LHI |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI. |
Gli obiettivi secondari sono determinare se BIIB093 migliora la sopravvivenza complessiva al Giorno 90 rispetto al placebo, se BIIB093 migliora l’esito funzionale al Giorno 90 sulla mRS dicotomizzata 0-4 vs 5-6, rispetto al placebo, se BIIB093 riduce lo spostamento della linea mediana a 72 ore (o al momento della craniectomia decompressiva [DC] o delle sole misure di conforto [CMO], se precedente) rispetto al placebo, e Valutare la sicurezza e la tollerabilità di BIIB093 nei soggetti con LHI. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory
2.A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions
3. Screening National Institutes of Health Stroke Scale (NIHSS) >=10
4. Study treatment infusion within 10 hours after time of symptom onset, if known, or the time last known normal
5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI
NOTE: Other protocol defined Inclusion criteria may apply
|
1. Diagnosi clinica di ictus ischemico acuto nel territorio dell’arteria cerebrale media (ACM) 2. Infarto emisferico massivo definito come: volume della lesione compreso tra 80 e 300 centimetri cubi (cm^3) alla risonanza magnetica (RM) con immagini pesate in diffusione (DWI) o alla perfusione tomografica computerizzata (CTP), oppure un punteggio TC precoce del Programma Alberta sull’ictus (ASPECTS) compreso tra 1 e 5 con coinvolgimento di almeno 2 regioni corticali definite 3. Punteggio della Scala dell’ictus del National Institutes of Health (NIHSS) allo screening >=10 4. Infusione del trattamento in studio entro 10 ore dopo il momento di esordio dei sintomi, se noto, o l’ultimo momento di normalità nota 5. Per i partecipanti sottoposti a trombectomia, l’inclusione nello studio deve basarsi sulla RM-DWI post-trombectomia. NOTA: possono essere applicati altri criteri di inclusione definiti dal protocollo |
|
E.4 | Principal exclusion criteria |
1.Participant is likely to have supportive care withdrawn on the first day
2.Commitment to decompressive craniectomy (DC) prior to enrollment
3.Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome
NOTE: Other protocol defined Exclusion criteria may apply
|
1. Probabile interruzione delle cure di supporto prestate al partecipante in occasione del primo giorno 2. Craniectomia decompressiva (CD) prevista prima dell’arruolamento 3. Evidenza di infarto concomitante nell’emisfero controlaterale sufficientemente grave da influire sugli esiti funzionali NOTA: possono essere applicati altri criteri di inclusione definiti dal protocollo
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of Participants with Improvement in Functional Outcome at Day 90 Assessed via the Modified Rankin Scale (mRS) |
Percentuale di partecipanti con miglioramento nell’esito funzionale al Giorno 90 valutato mediante la Scala modificata di Rankin (mRS)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline up to Day 90 |
dal basale al Giorno 90 |
|
E.5.2 | Secondary end point(s) |
1.Time to All-Cause Death [ Time Frame: Baseline up to Day 90 ] 2.Proportion of Participants who achieved mRS 0-4 at Day 90 [Time Frame: Baseline up to Day 90] 3.Reduction in Midline Shift at 72 Hours [ Time Frame: Baseline up to 72 Hours] 4.Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Baseline up to Day 90] |
1. Tempo al decesso per qualsiasi causa [intervallo di tempo: dal basale al Giorno 90] 2. Percentuale di partecipanti che hanno raggiunto un punteggio mRS di 0-4 al Giorno 90 [intervallo di tempo: dal basale al Giorno 90] 3. Riduzione nello spostamento della linea mediana a 72 ore [intervallo di tempo: dal basale a 72 ore] 4. Incidenza di eventi avversi (EA) ed eventi avversi seri (SAE) [intervallo di tempo: dal basale al Giorno 90]
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
#’s 1, 2 & 4 (Baseline up to Day 90) #3 (Baseline up to 72 hours) |
# 1, 2 e 4 (dal basale al Giorno 90) #3 (dal basale a 72 ore) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 68 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Brazil |
Canada |
Czechia |
Denmark |
Finland |
France |
Germany |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
Mexico |
Portugal |
Russian Federation |
Spain |
Switzerland |
Taiwan |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |